These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 14556835)
21. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Matrone C; Pivonello R; Colao A; Cappabianca P; Cavallo LM; Del Basso De Caro ML; Taylor JE; Culler MD; Lombardi G; Di Renzo GF; Annunziato L Neuroendocrinology; 2004 Mar; 79(3):142-8. PubMed ID: 15103227 [TBL] [Abstract][Full Text] [Related]
22. Expression and localisation of somatostatin receptor subtypes sst1-sst5 in areas of the rat medulla oblongata involved in autonomic regulation. Spary EJ; Maqbool A; Batten TF J Chem Neuroanat; 2008 Jan; 35(1):49-66. PubMed ID: 17646081 [TBL] [Abstract][Full Text] [Related]
23. [Efficacy of prolonged-release somatostatin analog monotherapy in metastatic endocrine tumors]. Kanyinda-K JM; Samalin E; Sebah H; Gallix B; Ychou M Gastroenterol Clin Biol; 2008 Dec; 32(12):989-91. PubMed ID: 18945567 [No Abstract] [Full Text] [Related]
24. Porcine somatostatin receptor 2 displays typical pharmacological sst2 features but unique dynamics of homodimerization and internalization. Durán-Prado M; Bucharles C; Gonzalez BJ; Vázquez-Martínez R; Martínez-Fuentes AJ; García-Navarro S; Rhodes SJ; Vaudry H; Malagón MM; Castaño JP Endocrinology; 2007 Jan; 148(1):411-21. PubMed ID: 17053026 [TBL] [Abstract][Full Text] [Related]
25. Use of lanreotide for the treatment of gastrointestinal fistulae. Clive K; Hardin M; White C; Larson C; Oh J; Cohn S Ann Surg; 2011 Jan; 253(1):211; author reply 211-2. PubMed ID: 21135689 [No Abstract] [Full Text] [Related]
26. Somatostatin-receptor mediated diagnosis and treatment in gastrointestinal neuroendocrine tumours (GEP-NET's). Oberg K Rocz Akad Med Bialymst; 2005; 50():62-8. PubMed ID: 16358941 [No Abstract] [Full Text] [Related]
27. Efficacy of lanreotide in preventing the occurrence of chemically induced hepatocellular carcinoma in rats. Borbath I; Leclercq IA; Sempoux C; Abarca-Quinones J; Desaeger C; Horsmans Y Chem Biol Interact; 2010 Jan; 183(1):238-48. PubMed ID: 19874807 [TBL] [Abstract][Full Text] [Related]
37. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas. Saveanu A; Jaquet P; Brue T; Barlier A Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980 [TBL] [Abstract][Full Text] [Related]
38. Somatostatin receptors and breast cancer. Cameron Smith M; Orlando C; Serio M; Maggi M J Endocrinol Invest; 2003; 26(8 Suppl):125-30. PubMed ID: 15233228 [No Abstract] [Full Text] [Related]
39. Somatostatin receptor ligands in the treatment of acromegaly. Gadelha MR; Wildemberg LE; Bronstein MD; Gatto F; Ferone D Pituitary; 2017 Feb; 20(1):100-108. PubMed ID: 28176162 [TBL] [Abstract][Full Text] [Related]
40. [Lanreotide++: a new therapeutic option in acromegaly]. Díez JJ Med Clin (Barc); 1996 Sep; 107(7):257-69. PubMed ID: 8975096 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]